Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Age is usually not considered when determining treatment for people with CLL, but this study indicates that older people with CLL may not respond as well to the therapy used for most patients.
The study was published Dec. 10 in the Journal of Clinical Oncology.
"Our analysis shows that optimal therapy for younger and older patients with chronic lymphocytic leukemia is likely to be different, at least when using current treatments," says first author Dr. Jennifer Woyach, assistant professor of hematology at the OSUCCC – James.
"We hope this study will shape future research by highlighting the importance of enrolling older patients on clinical trials and of developing trials that specifically target older patients."
Doctors diagnose about 15,000 new cases of chronic lymphocytic leukemia (CLL) annually in the United States, making it the most common form of leukemia. It remains incurable, and about 4,400 Americans die of the malignancy each year. CLL most often occurs in people older than age 65; the average age at diagnosis is 72. Yet, most
CLL clinical-trial participants are in their early 60s.
"Our findings apply to both routine care of CLL patients 70 years and older and to future CLL trials," says principal investigator Dr. John Byrd, a CLL specialist and professor of medicine, of medicinal chemistry and of veterinary biosciences at the OSUCCC – James.
"The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age," says Byrd, who is the D. Warren Brown Designated Chair in Leukemia Research.
"These data also show that future treatment trials for older adults with CLL should build on CD20 antibody therapies such as rituximab and ofatumumab, but not on fludarabine or alemtuzumab."
Byrd, Woyach and their colleagues reviewed 663 CLL patients who were enrolled in four sequential CLL clinical trials evaluating front-line therapies. The researchers looked for differences in treatment outcomes between older and younger patients to identify the most effective therapy for older adults.
The four trials, all sponsored by the Cancer and Leukemia Group B (CALGB) clinical cooperative group, compared these treatments: chlorambucil versus fludarabine, fludarabine plus rituximab versus fludarabine, fludarabine with consolidation alemtuzumab, and fludarabine plus rituximab with consolidation alemtuzumab.
Key conclusions include:
Ohio State University Medical Center: http://medicalcenter.osu.edu/Pages/index.aspx
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
NHS to sequence DNA of 75,000 patients over next four years
As the Ebola virus death toll rises in West Africa, New Scientist rounds up the best contenders for treatments and vaccines
Although smart watches and fitness bands are proliferating on wrists, there could be an even better spot on the body for wearable tech.
Studies show the caffeine in just a few cups of coffee enhances performance in a wide range of sports. But more isn't better, and concentrated caffeine can be lethal.
Leading scientists say spread of artemisinin-resistant parasites to Africa could prove disastrous
The health of infants is being put at risk as anti-vaccine groups discourage uptake of vitamin K for newborns, says Amanda Marcott
The lead in human teeth holds clues about where a person grew up and can help criminal investigators and archaeologists working with old or decomposed corpses, according to a University of Florida researcher.
West African countries are trying to contain the deadly disease
The Great War helped create the influenza pandemic of 1918, which eventually brought an early end to the Great War.
In 1986, a two-and-a-half year-old girl named Michelle Funk fell into a stream and drowned. By the time paramedics found her, she hadn’t been breathing for more than an hour. Her heart was stopped. In other words, she was dead.